HC Wainwright Issues Positive Estimate for LYEL Earnings

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) - Equities research analysts at HC Wainwright raised their Q1 2025 earnings per share estimates for Lyell Immunopharma in a research report issued on Thursday, March 13th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($0.17) per share for the quarter, up from their prior forecast of ($0.20). HC Wainwright currently has a "Neutral" rating and a $1.00 target price on the stock. The consensus estimate for Lyell Immunopharma's current full-year earnings is ($0.78) per share. HC Wainwright also issued estimates for Lyell Immunopharma's Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.73) EPS.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its quarterly earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.52). The business had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%.

Lyell Immunopharma Trading Down 6.0 %

LYEL stock traded down $0.03 during trading on Monday, reaching $0.55. The stock had a trading volume of 567,569 shares, compared to its average volume of 1,042,796. Lyell Immunopharma has a 52 week low of $0.48 and a 52 week high of $3.15. The stock's 50 day moving average is $0.62 and its two-hundred day moving average is $0.89. The firm has a market cap of $161.49 million, a PE ratio of -0.70 and a beta of -0.41.

Remove Ads

Insider Buying and Selling at Lyell Immunopharma

In related news, Director Richard Klausner purchased 158,000 shares of Lyell Immunopharma stock in a transaction on Friday, March 14th. The stock was acquired at an average price of $0.60 per share, for a total transaction of $94,800.00. Following the completion of the transaction, the director now directly owns 843,365 shares in the company, valued at $506,019. This represents a 23.05 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Lynn Seely purchased 175,000 shares of Lyell Immunopharma stock in a transaction on Friday, March 14th. The stock was bought at an average price of $0.61 per share, with a total value of $106,750.00. Following the transaction, the chief executive officer now owns 712,500 shares of the company's stock, valued at approximately $434,625. This represents a 32.56 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 533,000 shares of company stock valued at $313,550. 25.10% of the stock is owned by company insiders.

Institutional Trading of Lyell Immunopharma

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Centiva Capital LP purchased a new stake in Lyell Immunopharma in the third quarter worth about $31,000. Graham Capital Management L.P. purchased a new stake in shares of Lyell Immunopharma during the fourth quarter worth about $33,000. RPO LLC purchased a new stake in shares of Lyell Immunopharma during the fourth quarter worth about $42,000. Intech Investment Management LLC purchased a new stake in shares of Lyell Immunopharma during the third quarter worth about $52,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Lyell Immunopharma during the third quarter worth about $52,000. Hedge funds and other institutional investors own 66.05% of the company's stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.